RU2193036C2 - Производные имидазо[1,2-а]пиридина, способы их получения, фармацевтический препарат на их основе, способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которые вовлечено инфицирование h.pylori - Google Patents
Производные имидазо[1,2-а]пиридина, способы их получения, фармацевтический препарат на их основе, способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которые вовлечено инфицирование h.pylori Download PDFInfo
- Publication number
- RU2193036C2 RU2193036C2 RU99120178/04A RU99120178A RU2193036C2 RU 2193036 C2 RU2193036 C2 RU 2193036C2 RU 99120178/04 A RU99120178/04 A RU 99120178/04A RU 99120178 A RU99120178 A RU 99120178A RU 2193036 C2 RU2193036 C2 RU 2193036C2
- Authority
- RU
- Russia
- Prior art keywords
- formula
- pyridine
- compound according
- compound
- paragraphs
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 title claims abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- 230000005764 inhibitory process Effects 0.000 title claims description 7
- 230000027119 gastric acid secretion Effects 0.000 title claims description 5
- 238000003786 synthesis reaction Methods 0.000 title abstract description 58
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 206010019375 Helicobacter infections Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 197
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 210000004211 gastric acid Anatomy 0.000 claims abstract description 9
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- -1 2,6-diethylbenzylamino Chemical group 0.000 claims description 29
- 239000012442 inert solvent Substances 0.000 claims description 15
- 230000002496 gastric effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 7
- 210000001156 gastric mucosa Anatomy 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 150000007517 lewis acids Chemical class 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- PTNPMDOWMLEHSJ-UHFFFAOYSA-N [8-[(2,6-dimethylphenyl)methoxy]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C(C)=CN2C(CO)=C(C)N=C2C=1OCC1=C(C)C=CC=C1C PTNPMDOWMLEHSJ-UHFFFAOYSA-N 0.000 claims description 2
- MMHLWQWTEMTZKC-UHFFFAOYSA-N [8-[(2,6-dimethylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C(C)=CN2C(CO)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C MMHLWQWTEMTZKC-UHFFFAOYSA-N 0.000 claims description 2
- ZXWOLERJACOHEC-UHFFFAOYSA-N [8-[(2,6-dimethylphenyl)methylamino]-2-methylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C=CN2C(CO)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C ZXWOLERJACOHEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- MFPPVPQUXFXTIV-UHFFFAOYSA-N n-[(2-ethyl-6-methylphenyl)methyl]-2,3,6-trimethylimidazo[1,2-a]pyridin-8-amine Chemical compound CCC1=CC=CC(C)=C1CNC1=CC(C)=CN2C1=NC(C)=C2C MFPPVPQUXFXTIV-UHFFFAOYSA-N 0.000 claims description 2
- FNROZAJRIMXHMZ-UHFFFAOYSA-N n-[(4-chloro-2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=C(Cl)C=C1C FNROZAJRIMXHMZ-UHFFFAOYSA-N 0.000 claims description 2
- LUPBLBIGCPPRON-UHFFFAOYSA-N n-[(4-fluoro-2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C LUPBLBIGCPPRON-UHFFFAOYSA-N 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims 3
- 229940037467 helicobacter pylori Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- IVVSNSJMFLZNDJ-UHFFFAOYSA-N [8-[(2-ethyl-4-fluoro-6-methylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCC1=CC(F)=CC(C)=C1CNC1=CC(C)=CN2C1=NC(C)=C2CO IVVSNSJMFLZNDJ-UHFFFAOYSA-N 0.000 claims 1
- VPWZRONYARJIRI-UHFFFAOYSA-N [8-[(2-ethyl-6-methylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCC1=CC=CC(C)=C1CNC1=CC(C)=CN2C1=NC(C)=C2CO VPWZRONYARJIRI-UHFFFAOYSA-N 0.000 claims 1
- XXYWPYVBYQVLKY-UHFFFAOYSA-N [8-[(4-fluoro-2,6-dimethylphenyl)methoxy]-2-methylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C=CN2C(CO)=C(C)N=C2C=1OCC1=C(C)C=C(F)C=C1C XXYWPYVBYQVLKY-UHFFFAOYSA-N 0.000 claims 1
- ZHWSJGHFRJVNLP-UHFFFAOYSA-N [8-[(4-fluoro-2,6-dimethylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C(C)=CN2C(CO)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C ZHWSJGHFRJVNLP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZXJBLBADKNTHPO-UHFFFAOYSA-N n-[(2,6-dimethylphenyl)methyl]-2,3,6-trimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(C)=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C ZXJBLBADKNTHPO-UHFFFAOYSA-N 0.000 claims 1
- RPMMKZINBGZQDN-UHFFFAOYSA-N n-[(2-ethyl-4-fluoro-6-methylphenyl)methyl]-2,3,6-trimethylimidazo[1,2-a]pyridin-8-amine Chemical compound CCC1=CC(F)=CC(C)=C1CNC1=CC(C)=CN2C1=NC(C)=C2C RPMMKZINBGZQDN-UHFFFAOYSA-N 0.000 claims 1
- AXXKYAJAPLKEEE-UHFFFAOYSA-N n-[(4-fluoro-2,6-dimethylphenyl)methyl]-2,3,6-trimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(C)=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C AXXKYAJAPLKEEE-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 192
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 78
- 239000000203 mixture Substances 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- 238000005160 1H NMR spectroscopy Methods 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 239000002904 solvent Substances 0.000 description 36
- 238000010898 silica gel chromatography Methods 0.000 description 35
- 239000003480 eluent Substances 0.000 description 32
- 239000012044 organic layer Substances 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 13
- 235000009518 sodium iodide Nutrition 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- 239000011734 sodium Substances 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 9
- 239000011592 zinc chloride Substances 0.000 description 9
- 235000005074 zinc chloride Nutrition 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- HPVRFWQMBYLJRL-UHFFFAOYSA-N 2-(chloromethyl)-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1CCl HPVRFWQMBYLJRL-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- HYFDMAKFLLWGOK-UHFFFAOYSA-N 2-(bromomethyl)-5-fluoro-1,3-dimethylbenzene Chemical compound CC1=CC(F)=CC(C)=C1CBr HYFDMAKFLLWGOK-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- BNBOUFHCTIFWHN-UHFFFAOYSA-N 3-bromobutan-2-one Chemical compound CC(Br)C(C)=O BNBOUFHCTIFWHN-UHFFFAOYSA-N 0.000 description 5
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- ZFKUUYLAFYWZSS-UHFFFAOYSA-N 2,3,6-trimethylimidazo[1,2-a]pyridin-8-amine Chemical compound NC1=CC(C)=CN2C(C)=C(C)N=C21 ZFKUUYLAFYWZSS-UHFFFAOYSA-N 0.000 description 4
- QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 4
- UIEARKBMUATCNI-UHFFFAOYSA-N 2-(chloromethyl)-1-ethyl-3-methylbenzene Chemical compound CCC1=CC=CC(C)=C1CCl UIEARKBMUATCNI-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000009858 acid secretion Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- JCYLOXBHTIKQGL-UHFFFAOYSA-N ethyl 8-amino-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound NC1=CC(C)=CN2C(C(=O)OCC)=C(C)N=C21 JCYLOXBHTIKQGL-UHFFFAOYSA-N 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PESVDKISSIUPTJ-UHFFFAOYSA-N 2,6-diethylbenzaldehyde Chemical compound CCC1=CC=CC(CC)=C1C=O PESVDKISSIUPTJ-UHFFFAOYSA-N 0.000 description 3
- TVNROUIUGVLBOP-UHFFFAOYSA-N 2-(bromomethyl)-1-ethyl-5-fluoro-3-methylbenzene Chemical compound CCC1=CC(F)=CC(C)=C1CBr TVNROUIUGVLBOP-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 3
- LFWGLUUYTBFHPH-UHFFFAOYSA-N ethyl 8-[(2,6-dimethylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(C)=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C LFWGLUUYTBFHPH-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- RTUABNJRTRJMMS-UHFFFAOYSA-N 2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound NC1=CC=CN2C(C)=C(C)N=C21 RTUABNJRTRJMMS-UHFFFAOYSA-N 0.000 description 2
- QUEDYNFRLQIQHB-UHFFFAOYSA-N 2-ethyl-6-methylbenzaldehyde Chemical compound CCC1=CC=CC(C)=C1C=O QUEDYNFRLQIQHB-UHFFFAOYSA-N 0.000 description 2
- ZCUFAWPRMNPHJV-UHFFFAOYSA-N 3-[(2,6-dimethylphenyl)methoxy]-5-methyl-2-nitropyridine Chemical compound CC1=CN=C([N+]([O-])=O)C(OCC=2C(=CC=CC=2C)C)=C1 ZCUFAWPRMNPHJV-UHFFFAOYSA-N 0.000 description 2
- FANMFAXGQCUEDQ-UHFFFAOYSA-N 3-[(2,6-dimethylphenyl)methoxy]-5-methylpyridin-2-amine Chemical compound CC1=CN=C(N)C(OCC=2C(=CC=CC=2C)C)=C1 FANMFAXGQCUEDQ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- YRGMYJUKFJPNPD-UHFFFAOYSA-N 5-bromopyridine-2,3-diamine Chemical compound NC1=CC(Br)=CN=C1N YRGMYJUKFJPNPD-UHFFFAOYSA-N 0.000 description 2
- LDYYBZNEWDTDEE-UHFFFAOYSA-N 5-fluoro-3-nitropyridin-2-amine Chemical compound NC1=NC=C(F)C=C1[N+]([O-])=O LDYYBZNEWDTDEE-UHFFFAOYSA-N 0.000 description 2
- MGBUJACQIBNLAU-UHFFFAOYSA-N 5-fluoropyridine-2,3-diamine Chemical compound NC1=CC(F)=CN=C1N MGBUJACQIBNLAU-UHFFFAOYSA-N 0.000 description 2
- AITFREYTVOPXOT-UHFFFAOYSA-N 5-methylpyridine-2,3-diamine Chemical compound CC1=CN=C(N)C(N)=C1 AITFREYTVOPXOT-UHFFFAOYSA-N 0.000 description 2
- JNXOWVWCTOFBPU-UHFFFAOYSA-N 6-bromo-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound NC1=CC(Br)=CN2C(C)=C(C)N=C21 JNXOWVWCTOFBPU-UHFFFAOYSA-N 0.000 description 2
- DHAJJQBDKCFWDJ-UHFFFAOYSA-N 6-chloro-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound NC1=CC(Cl)=CN2C(C)=C(C)N=C21 DHAJJQBDKCFWDJ-UHFFFAOYSA-N 0.000 description 2
- UPCHOXFZBHFRHX-UHFFFAOYSA-N 6-fluoro-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound NC1=CC(F)=CN2C(C)=C(C)N=C21 UPCHOXFZBHFRHX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 0 CC(C1C(C)=CC(*)=CC1*)=O Chemical compound CC(C1C(C)=CC(*)=CC1*)=O 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 108010079943 Pentagastrin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 2
- 229960002129 cefixime Drugs 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 2
- 229960002549 enoxacin Drugs 0.000 description 2
- PGVMMZUJMRHFEI-UHFFFAOYSA-N ethyl 6-bromo-8-[(4-fluoro-2,6-dimethylphenyl)methylamino]-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(Br)=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C PGVMMZUJMRHFEI-UHFFFAOYSA-N 0.000 description 2
- LBINVIAEGIDNJC-UHFFFAOYSA-N ethyl 8-[(2-ethyl-4-fluoro-6-methylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(C)=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1CC LBINVIAEGIDNJC-UHFFFAOYSA-N 0.000 description 2
- HSEXCMBLIFULGZ-UHFFFAOYSA-N ethyl 8-[(2-ethyl-6-methylphenyl)methoxy]-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C=CN2C(C(=O)OCC)=C(C)N=C2C=1OCC1=C(C)C=CC=C1CC HSEXCMBLIFULGZ-UHFFFAOYSA-N 0.000 description 2
- CFLUMUCJCPNPQG-UHFFFAOYSA-N ethyl 8-[(4-fluoro-2,6-dimethylphenyl)methoxy]-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C=CN2C(C(=O)OCC)=C(C)N=C2C=1OCC1=C(C)C=C(F)C=C1C CFLUMUCJCPNPQG-UHFFFAOYSA-N 0.000 description 2
- KANUDPSCIATZHX-UHFFFAOYSA-N ethyl 8-[(4-fluoro-2,6-dimethylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(C)=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C KANUDPSCIATZHX-UHFFFAOYSA-N 0.000 description 2
- RWPAXRHWORQNQS-UHFFFAOYSA-N ethyl 8-amino-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound NC1=CC=CN2C(C(=O)OCC)=C(C)N=C21 RWPAXRHWORQNQS-UHFFFAOYSA-N 0.000 description 2
- UFGXEVHBHHUYMU-UHFFFAOYSA-N ethyl 8-hydroxy-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound OC1=CC=CN2C(C(=O)OCC)=C(C)N=C21 UFGXEVHBHHUYMU-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000005232 imidazopyridines Chemical group 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000005905 mesyloxy group Chemical group 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960000564 nitrofurantoin Drugs 0.000 description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
- 229960000444 pentagastrin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridine hydrochloride Substances [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- PVDKNKUVHSULSN-UHFFFAOYSA-N 1-(bromomethyl)-3-fluoro-5-methylbenzene Chemical compound CC1=CC(F)=CC(CBr)=C1 PVDKNKUVHSULSN-UHFFFAOYSA-N 0.000 description 1
- CHMJJIHXWABUHA-UHFFFAOYSA-N 1-(chloromethyl)-2,3-dimethylbenzene Chemical compound CC1=CC=CC(CCl)=C1C CHMJJIHXWABUHA-UHFFFAOYSA-N 0.000 description 1
- RCWIWNUVHNAUQC-UHFFFAOYSA-N 1-fluoro-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(F)=C1 RCWIWNUVHNAUQC-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- WGDXYOKSBKQFSP-UHFFFAOYSA-N 2,3-dimethylimidazo[1,2-a]pyridin-8-ol Chemical compound OC1=CC=CN2C(C)=C(C)N=C21 WGDXYOKSBKQFSP-UHFFFAOYSA-N 0.000 description 1
- VGVGFZRSKWISBH-UHFFFAOYSA-N 2,6-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C1=C(C)C=C(N)C2=NC(C)=CN21 VGVGFZRSKWISBH-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- FHHVEUQPKNBWMT-UHFFFAOYSA-N 2-(bromomethyl)-1-chloro-3,5-dimethylbenzene Chemical compound CC1=CC(C)=C(CBr)C(Cl)=C1 FHHVEUQPKNBWMT-UHFFFAOYSA-N 0.000 description 1
- FYIVZEYEURWVDB-UHFFFAOYSA-N 2-(bromomethyl)-5-chloro-1,3-dimethylbenzene Chemical compound CC1=CC(Cl)=CC(C)=C1CBr FYIVZEYEURWVDB-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- OQTSACHWSVSGQR-UHFFFAOYSA-N 3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-ol Chemical compound OC1=CC=CN2C(CO)=C(C)N=C21 OQTSACHWSVSGQR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZRCMCGQDIYNWDX-UHFFFAOYSA-N 5-chloropyridine-2,3-diamine Chemical compound NC1=CC(Cl)=CN=C1N ZRCMCGQDIYNWDX-UHFFFAOYSA-N 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 1
- FESHDHSFWWFFFN-UHFFFAOYSA-N 5-methyl-2-nitropyridin-3-ol Chemical compound CC1=CN=C([N+]([O-])=O)C(O)=C1 FESHDHSFWWFFFN-UHFFFAOYSA-N 0.000 description 1
- BSWGQFCXSOJUHC-UHFFFAOYSA-N 6-bromo-n-[(2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(Br)=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C BSWGQFCXSOJUHC-UHFFFAOYSA-N 0.000 description 1
- SSFNCOGEFRXHFX-UHFFFAOYSA-N 6-chloro-n-[(2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(Cl)=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C SSFNCOGEFRXHFX-UHFFFAOYSA-N 0.000 description 1
- ZZHNYWHADLVCEP-UHFFFAOYSA-N 8-[(2,6-dimethylphenyl)methoxy]-2,3-dimethylimidazo[1,2-a]pyridine Chemical compound C=1C=CN2C(C)=C(C)N=C2C=1OCC1=C(C)C=CC=C1C ZZHNYWHADLVCEP-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 241000260897 Acidota Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010061000 Benign pancreatic neoplasm Diseases 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- PTRHQNSPHOXFKS-UHFFFAOYSA-N CC(C(C=C(C)C=C1NCc2c(C)cccc2C)C1=C1)=C1N Chemical compound CC(C(C=C(C)C=C1NCc2c(C)cccc2C)C1=C1)=C1N PTRHQNSPHOXFKS-UHFFFAOYSA-N 0.000 description 1
- GCXFPWLLCUEOOP-UHFFFAOYSA-N CC(C(C=C(C=C1NCc2c(C)cccc2C)F)C1=C1)=C1N Chemical compound CC(C(C=C(C=C1NCc2c(C)cccc2C)F)C1=C1)=C1N GCXFPWLLCUEOOP-UHFFFAOYSA-N 0.000 description 1
- FNWHIDQRSKNBQD-UHFFFAOYSA-N CCC(C(C=C(C)C=C1NCc2c(CC)cccc2C)C1=C1)=C1N Chemical compound CCC(C(C=C(C)C=C1NCc2c(CC)cccc2C)C1=C1)=C1N FNWHIDQRSKNBQD-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000035944 Duodenal fistula Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
- CQNRAENHOQEDHA-UHFFFAOYSA-N [6-bromo-8-[(4-fluoro-2,6-dimethylphenyl)methylamino]-2-methylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C(Br)=CN2C(CO)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C CQNRAENHOQEDHA-UHFFFAOYSA-N 0.000 description 1
- IGORZTUCIDSFDL-UHFFFAOYSA-N [8-[(2,6-diethylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCC1=CC=CC(CC)=C1CNC1=CC(C)=CN2C1=NC(C)=C2CO IGORZTUCIDSFDL-UHFFFAOYSA-N 0.000 description 1
- MTJNMXVWGOVDKE-UHFFFAOYSA-N [8-[(2-ethyl-6-methylphenyl)methoxy]-2-methylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CCC1=CC=CC(C)=C1COC1=CC=CN2C1=NC(C)=C2CO MTJNMXVWGOVDKE-UHFFFAOYSA-N 0.000 description 1
- QLSGIWLQYNQCFJ-UHFFFAOYSA-N [8-[(4-fluoro-2,6-dimethylphenyl)methylamino]-2-methylimidazo[1,2-a]pyridin-3-yl]methanol Chemical compound C=1C=CN2C(CO)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C QLSGIWLQYNQCFJ-UHFFFAOYSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000031112 adenoma of pancreas Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- 229960004645 bismuth subcitrate Drugs 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- MYROJEHAMGGVTO-UHFFFAOYSA-N ethyl 2-methyl-8-(2-phenylpropan-2-ylamino)imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C(=O)(OCC)C1=C(N=C2N1C=CC=C2NC(C2=CC=CC=C2)(C)C)C MYROJEHAMGGVTO-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- UVTLYMPJRXHJGK-UHFFFAOYSA-N ethyl 8-[(2,6-diethylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(C)=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(CC)C=CC=C1CC UVTLYMPJRXHJGK-UHFFFAOYSA-N 0.000 description 1
- ZEIUQDJMHWCCRD-UHFFFAOYSA-N ethyl 8-[(2,6-dimethylphenyl)methoxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(C)=CN2C(C(=O)OCC)=C(C)N=C2C=1OCC1=C(C)C=CC=C1C ZEIUQDJMHWCCRD-UHFFFAOYSA-N 0.000 description 1
- ZWILXXXADQMYMR-UHFFFAOYSA-N ethyl 8-[(2-ethyl-6-methylphenyl)methylamino]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C(C)=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(C)C=CC=C1CC ZWILXXXADQMYMR-UHFFFAOYSA-N 0.000 description 1
- VBXSMKNCICXFLA-UHFFFAOYSA-N ethyl 8-[(4-fluoro-2,6-dimethylphenyl)methylamino]-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound C=1C=CN2C(C(=O)OCC)=C(C)N=C2C=1NCC1=C(C)C=C(F)C=C1C VBXSMKNCICXFLA-UHFFFAOYSA-N 0.000 description 1
- KLWDLSDMYZHEPC-UHFFFAOYSA-N ethyl 8-amino-6-bromo-2-methylimidazo[1,2-a]pyridine-3-carboxylate Chemical compound NC1=CC(Br)=CN2C(C(=O)OCC)=C(C)N=C21 KLWDLSDMYZHEPC-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- OSVXOXPIOPBKQC-UHFFFAOYSA-N n-[(2,6-diethylphenyl)methyl]-2,3,6-trimethylimidazo[1,2-a]pyridin-8-amine Chemical compound CCC1=CC=CC(CC)=C1CNC1=CC(C)=CN2C1=NC(C)=C2C OSVXOXPIOPBKQC-UHFFFAOYSA-N 0.000 description 1
- LPEPDTHLQAYLQJ-UHFFFAOYSA-N n-[(2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C LPEPDTHLQAYLQJ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9700661A SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | New compounds |
| SE9700661-3 | 1997-02-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU99120178A RU99120178A (ru) | 2001-08-10 |
| RU2193036C2 true RU2193036C2 (ru) | 2002-11-20 |
Family
ID=20405920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU99120178/04A RU2193036C2 (ru) | 1997-02-25 | 1998-02-17 | Производные имидазо[1,2-а]пиридина, способы их получения, фармацевтический препарат на их основе, способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которые вовлечено инфицирование h.pylori |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6265415B1 (https=) |
| EP (1) | EP0971920B1 (https=) |
| JP (1) | JP2001512477A (https=) |
| KR (1) | KR20000075622A (https=) |
| CN (1) | CN1100056C (https=) |
| AR (1) | AR011134A1 (https=) |
| AT (1) | ATE218569T1 (https=) |
| AU (1) | AU723389B2 (https=) |
| BR (1) | BR9807457A (https=) |
| CA (1) | CA2280008A1 (https=) |
| CZ (1) | CZ291681B6 (https=) |
| DE (1) | DE69805787T2 (https=) |
| DK (1) | DK0971920T3 (https=) |
| EE (1) | EE04016B1 (https=) |
| ES (1) | ES2178169T3 (https=) |
| HU (1) | HUP0000720A3 (https=) |
| ID (1) | ID22218A (https=) |
| IL (1) | IL131122A0 (https=) |
| IS (1) | IS1901B (https=) |
| MY (1) | MY118822A (https=) |
| NO (1) | NO313009B1 (https=) |
| NZ (1) | NZ336878A (https=) |
| PL (1) | PL190379B1 (https=) |
| PT (1) | PT971920E (https=) |
| RU (1) | RU2193036C2 (https=) |
| SE (1) | SE9700661D0 (https=) |
| SK (1) | SK283903B6 (https=) |
| TR (1) | TR199902060T2 (https=) |
| TW (1) | TW568907B (https=) |
| UA (1) | UA64741C2 (https=) |
| WO (1) | WO1998037080A1 (https=) |
| ZA (1) | ZA981134B (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2348634C2 (ru) * | 2003-06-26 | 2009-03-10 | Астразенека Аб | Новое имидазопиридиновое соединение i с терапевтическим действием |
| RU2373206C2 (ru) * | 2004-04-22 | 2009-11-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединение имидазопиридина |
| RU2397170C2 (ru) * | 2004-09-03 | 2010-08-20 | Юхан Корпорейшн | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-b]ПИРИДИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| RU2441003C2 (ru) * | 2006-07-03 | 2012-01-27 | Санофи-Авентис | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ |
| RU2608611C2 (ru) * | 2009-11-05 | 2017-01-23 | Юниверсити Оф Нотр Дам Дю Лак | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
| JPH10502365A (ja) * | 1994-07-01 | 1998-03-03 | リカン・リミテッド | ヘリコバクタータンパク質およびワクチン |
| WO1997025429A1 (en) * | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
| SE9602286D0 (sv) | 1996-06-10 | 1996-06-10 | Astra Ab | New compounds |
| SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| SE9802794D0 (sv) * | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
| DE10001037C1 (de) | 2000-01-13 | 2001-12-13 | Byk Gulden Lomberg Chem Fab | Verfahren und Zwischenprodukte zur Herstellung von Imidazopyridinen |
| UA80393C2 (uk) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| JP2005506322A (ja) * | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種 |
| DE10145457A1 (de) | 2001-09-14 | 2003-04-03 | Basf Ag | Substituierte Imidazo[1,2-a]-5,6,7,8-tetrahydropyridin-8-one, Verfahren zu ihrer Herstellung, sowie deren Verwendung zur Herstellung von Imidazo[1,2,-a]pyridinen |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ATE378336T1 (de) | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| PT1606261E (pt) | 2003-03-10 | 2010-01-11 | Nycomed Gmbh | Novo processo para a preparação de roflumilast |
| WO2005026164A1 (en) * | 2003-09-18 | 2005-03-24 | Altana Pharma Ag | Pharmacologically active imidazo[4,5-c]pyridines |
| EP1682133A1 (en) | 2003-11-03 | 2006-07-26 | AstraZeneca AB | Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux |
| SE0303451D0 (sv) * | 2003-12-18 | 2003-12-18 | Astrazeneca Ab | New compounds |
| ATE527258T1 (de) | 2004-07-28 | 2011-10-15 | Takeda Pharmaceutical | Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung |
| DK1784404T3 (da) | 2004-09-03 | 2012-02-13 | Yuhan Corp | Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling |
| MX2007002214A (es) | 2004-09-03 | 2007-05-07 | Yuhan Corp | Derivados de pirrolo[3,2-c]piridina y procesos para su preparacion. |
| KR101068355B1 (ko) * | 2005-03-09 | 2011-09-28 | 주식회사유한양행 | 신규의 이미다조[1,2-ａ]피리딘 유도체 및 그의 제조방법 |
| US8663694B2 (en) * | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| PE20061110A1 (es) * | 2005-03-24 | 2006-10-20 | Glaxo Group Ltd | Derivados de imidazopiridina como antagonistas de la bomba de acido (apa) |
| DE602006018354D1 (de) | 2005-12-05 | 2010-12-30 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| KR101146852B1 (ko) | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
| CA2836202A1 (en) | 2011-05-30 | 2012-12-06 | Astellas Pharma Inc. | Imidazopyridine compounds |
| CA2891976C (en) * | 2012-11-30 | 2020-07-21 | Astellas Pharma Inc. | Imidazopyridine compounds |
| CN120117960A (zh) * | 2025-05-12 | 2025-06-10 | 天津全和诚科技有限责任公司 | 一种杂质化合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0033094A1 (en) * | 1980-01-23 | 1981-08-05 | Schering Corporation | Imidazo(1,2-a)pyridines, processes for their preparation and pharmaceutical compositions containing them |
| EP0204285A1 (en) * | 1985-06-04 | 1986-12-10 | Fujisawa Pharmaceutical Co., Ltd. | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them |
| RU2051917C1 (ru) * | 1988-02-03 | 1996-01-10 | Хиноин Дъедъсер еш Ведъесети Термекек Дъяра РТ | Производные амида 4-оксо-4н-пиридо(1,2-a)-пиримидин-3-карбоновой кислоты или их кислотно-аддитивные соли |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0228006A1 (en) * | 1985-12-16 | 1987-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
-
1997
- 1997-02-25 SE SE9700661A patent/SE9700661D0/xx unknown
-
1998
- 1998-02-11 ZA ZA981134A patent/ZA981134B/xx unknown
- 1998-02-11 AR ARP980100614A patent/AR011134A1/es active IP Right Grant
- 1998-02-17 DE DE69805787T patent/DE69805787T2/de not_active Expired - Fee Related
- 1998-02-17 US US09/043,040 patent/US6265415B1/en not_active Expired - Lifetime
- 1998-02-17 AU AU63147/98A patent/AU723389B2/en not_active Ceased
- 1998-02-17 UA UA99084654A patent/UA64741C2/uk unknown
- 1998-02-17 AT AT98907306T patent/ATE218569T1/de not_active IP Right Cessation
- 1998-02-17 EE EEP199900367A patent/EE04016B1/xx not_active IP Right Cessation
- 1998-02-17 IL IL13112298A patent/IL131122A0/xx not_active IP Right Cessation
- 1998-02-17 TW TW087102208A patent/TW568907B/zh active
- 1998-02-17 CZ CZ19993014A patent/CZ291681B6/cs not_active IP Right Cessation
- 1998-02-17 NZ NZ336878A patent/NZ336878A/en unknown
- 1998-02-17 ID IDW990903A patent/ID22218A/id unknown
- 1998-02-17 PT PT98907306T patent/PT971920E/pt unknown
- 1998-02-17 RU RU99120178/04A patent/RU2193036C2/ru not_active IP Right Cessation
- 1998-02-17 HU HU0000720A patent/HUP0000720A3/hu unknown
- 1998-02-17 ES ES98907306T patent/ES2178169T3/es not_active Expired - Lifetime
- 1998-02-17 SK SK1099-99A patent/SK283903B6/sk unknown
- 1998-02-17 CN CN98802784A patent/CN1100056C/zh not_active Expired - Fee Related
- 1998-02-17 PL PL98335485A patent/PL190379B1/pl not_active IP Right Cessation
- 1998-02-17 JP JP53654998A patent/JP2001512477A/ja not_active Ceased
- 1998-02-17 WO PCT/SE1998/000275 patent/WO1998037080A1/en not_active Ceased
- 1998-02-17 DK DK98907306T patent/DK0971920T3/da active
- 1998-02-17 KR KR1019997007685A patent/KR20000075622A/ko not_active Abandoned
- 1998-02-17 BR BR9807457-1A patent/BR9807457A/pt not_active IP Right Cessation
- 1998-02-17 TR TR1999/02060T patent/TR199902060T2/xx unknown
- 1998-02-17 CA CA002280008A patent/CA2280008A1/en not_active Abandoned
- 1998-02-17 EP EP98907306A patent/EP0971920B1/en not_active Expired - Lifetime
- 1998-02-23 MY MYPI98000774A patent/MY118822A/en unknown
-
1999
- 1999-08-05 IS IS5148A patent/IS1901B/is unknown
- 1999-08-24 NO NO19994078A patent/NO313009B1/no unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0033094A1 (en) * | 1980-01-23 | 1981-08-05 | Schering Corporation | Imidazo(1,2-a)pyridines, processes for their preparation and pharmaceutical compositions containing them |
| EP0204285A1 (en) * | 1985-06-04 | 1986-12-10 | Fujisawa Pharmaceutical Co., Ltd. | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them |
| RU2051917C1 (ru) * | 1988-02-03 | 1996-01-10 | Хиноин Дъедъсер еш Ведъесети Термекек Дъяра РТ | Производные амида 4-оксо-4н-пиридо(1,2-a)-пиримидин-3-карбоновой кислоты или их кислотно-аддитивные соли |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2348634C2 (ru) * | 2003-06-26 | 2009-03-10 | Астразенека Аб | Новое имидазопиридиновое соединение i с терапевтическим действием |
| RU2373206C2 (ru) * | 2004-04-22 | 2009-11-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединение имидазопиридина |
| RU2397170C2 (ru) * | 2004-09-03 | 2010-08-20 | Юхан Корпорейшн | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-b]ПИРИДИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| RU2441003C2 (ru) * | 2006-07-03 | 2012-01-27 | Санофи-Авентис | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ |
| RU2608611C2 (ru) * | 2009-11-05 | 2017-01-23 | Юниверсити Оф Нотр Дам Дю Лак | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2193036C2 (ru) | Производные имидазо[1,2-а]пиридина, способы их получения, фармацевтический препарат на их основе, способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которые вовлечено инфицирование h.pylori | |
| RU2238271C2 (ru) | Производные имидазопиридина, способы их получения и промежуточные соединения, фармацевтический препарат на их основе (варианты), способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которых вовлечено инфицирование h.pylori | |
| JP2001525322A (ja) | 胃酸分泌を抑制する複素環式化合物、それらの製造法およびそれらの医薬組成物 | |
| EP1105390B1 (en) | Imidazo[1,2-a]pyridine derivatives for the treatment of gastrointestinal diseases | |
| HK1024248B (en) | Compounds for inhibition of gastric acid secretion | |
| MXPA99007650A (en) | Compounds for inhibition of gastric acid secretion | |
| MXPA01001720A (en) | New compounds | |
| HK1036274B (en) | Imidazo (1,2-a) pyridine derivatives for the treatment of gastrointestinal diseases | |
| HK1033317B (en) | Imidazo pyridine derivatives which inhibit gastric acid secretion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20060218 |